This company listing is no longer active
Blueprint Medicines (1BPMC) Stock Overview
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
1BPMC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Blueprint Medicines Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$105.10 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.90 |
| 1 Month Change | -2.41% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BPMC | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | -0.1% |
| 1Y | n/a | 18.9% | 20.2% |
Return vs Industry: Insufficient data to determine how 1BPMC performed against the Italian Biotechs industry.
Return vs Market: Insufficient data to determine how 1BPMC performed against the Italian Market.
Price Volatility
| 1BPMC volatility | |
|---|---|
| 1BPMC Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.0% |
| 10% least volatile stocks in IT Market | 2.5% |
Stable Share Price: 1BPMC's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: Insufficient data to determine 1BPMC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 685 | Kate Haviland | www.blueprintmedicines.com |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
Blueprint Medicines Corporation Fundamentals Summary
| 1BPMC fundamental statistics | |
|---|---|
| Market cap | €7.22b |
| Earnings (TTM) | -€134.27m |
| Revenue (TTM) | €484.66m |
Is 1BPMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BPMC income statement (TTM) | |
|---|---|
| Revenue | US$562.12m |
| Cost of Revenue | US$19.77m |
| Gross Profit | US$542.35m |
| Other Expenses | US$698.08m |
| Earnings | -US$155.73m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 96.48% |
| Net Profit Margin | -27.70% |
| Debt/Equity Ratio | 185.4% |
How did 1BPMC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/17 04:00 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Blueprint Medicines Corporation is covered by 10 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Farmer | BMO Capital Markets Equity Research |
| Dane Leone | BTIG |
| Arlinda Lee | Canaccord Genuity |